BXP — Beximco Pharmaceuticals Balance Sheet
0.000.00%
- £196.29m
- £244.13m
- BDT44.39bn
- 93
- 96
- 78
- 100
Annual balance sheet for Beximco Pharmaceuticals, fiscal year end - June 30th, BDT millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | BAS | BAS | BAS | BAS | BAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 635 | 675 | 1,169 | 1,136 | 1,054 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,753 | 3,388 | 3,996 | 4,379 | 4,465 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13,049 | 13,771 | 18,419 | 20,876 | 20,818 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 35,241 | 36,531 | 42,379 | 42,808 | 43,049 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 50,119 | 52,246 | 66,148 | 69,157 | 69,344 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,358 | 9,350 | 12,736 | 13,265 | 9,562 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 17,624 | 15,216 | 25,548 | 25,476 | 21,394 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 32,495 | 37,031 | 40,600 | 43,681 | 47,950 |
| Total Liabilities & Shareholders' Equity | 50,119 | 52,246 | 66,148 | 69,157 | 69,344 |
| Total Common Shares Outstanding |